Zhang Hai-Chao, Wang Na, Zhang Wen, Gu Zhi-Chun, Liu Xiao-Yan
Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai Department of Pharmacy, The Second Affiliated Hospital of Chongqing Medical University Chongqing Medical University, Chongqing, China.
Medicine (Baltimore). 2018 Sep;97(36):e12203. doi: 10.1097/MD.0000000000012203.
Pulmonary arterial hypertension (PAH) is an incurable disease with high mortality. Although most studies recommend anticoagulation treatment for idiopathic pulmonary arterial hypertension (IPAH), the survival benefits are uncertain. Therefore, the present paper provides a protocol to investigate this issue by a meta-analysis.
An electronic search will be performed for randomized controlled trials (RCTs) or cohort studies that reported the interested efficacy data (pulmonary arterial pressure and survival advantage) in anticoagulants-treated patients with PAH. Hazard ratios with their confidence intervals will be calculated using a fixed- or random-effects model.
This study will provide the survival benefits of anticoagulants in PAH patients by pooling the results of individual studies.
The results will bring about vigorous evidence in this issue and guide both clinical decision-making and future research.
肺动脉高压（PAH）是一种无法治愈且死亡率高的疾病。尽管大多数研究推荐对特发性肺动脉高压（IPAH）进行抗凝治疗，但其生存获益尚不确定。因此，本文提供一项通过荟萃分析来研究该问题的方案。
将对随机对照试验（RCT）或队列研究进行电子检索，这些研究报告了接受抗凝治疗的PAH患者的相关疗效数据（肺动脉压和生存优势）。将使用固定效应或随机效应模型计算风险比及其置信区间。
本研究将通过汇总个体研究结果，提供抗凝剂对PAH患者的生存获益情况。
研究结果将为该问题提供有力证据，并指导临床决策和未来研究。
